Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration...
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
About this item
Full title
Author / Creator
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Investigators have extensively explored the short-term safety and efficacy data on 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature is reported on the long-term outcome of these patients. The current goal of this study is focused on the long-term outcome of mCRPC patients treated with 177Lu-PSMA-617 RLT.
Amo...
Alternative Titles
Full title
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_2524841460
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2524841460
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0251375
